SCHEMBL6467359

SCHEMBL6467359

CCN(CCO)CCOc1ccc2nc(Nc3nc(C)c4cc(OC)c(OC)cc4n3)nc(OC(=O)C(F)(F)F)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 1/20 0.37
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
KDR P35968 7/20 0.35
AURKA O14965 1/20 0.35
EGFR P00533 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
PSMD14 O00487 1/20 0.34
APAF1 O14727 1/20 0.34
MITF O75030 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
PTK2B Q14289 1/20 0.34
TLR7 Q9NYK1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6467450 0.96 FGFR2 (0.40) FGFR2MEN1ALDH1A1KMT2AUSP2
SCHEMBL6467974 0.95 KDR (0.38) MEN1ALDH1A1KMT2AUSP2LMNA
SCHEMBL6469291 0.93 MCHR1 (0.35) MEN1ALDH1A1KMT2AUSP2LMNA
SCHEMBL6468701 0.91 CSF1R (0.38) FGFR2MEN1ALDH1A1KMT2AUSP2
SCHEMBL6467480 0.91 TLR7 (0.34) FGFR2MEN1ALDH1A1KMT2AUSP2
SCHEMBL6467467 0.90 TDP2 (0.38) MEN1ALDH1A1KMT2AUSP2LMNA
SCHEMBL6469716 0.89 ALDH1A1 (0.37) MEN1ALDH1A1KMT2AUSP2LMNA
SCHEMBL6467888 0.89 TDP2 (0.36) MEN1ALDH1A1KMT2AUSP2LMNA
SCHEMBL6467169 0.88 MAPT (0.37) FGFR2MEN1ALDH1A1KMT2AUSP2
Trifluoroacetic Acid SCHEMBL6467347 0.88 FGFR2 (0.38) FGFR2MEN1ALDH1A1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB FGFR2 4843/4885MEN1 4218/4885ALDH1A1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.